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ABSTRACT 
Background: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a curative treatment option for 
many patients with Acute Myeloid Leukemia (AML); however, it can lead to complications of Graft-Versus-
Host-Disease (GVHD) which can affect the quality of life and overall survival. The aim of this study was to 
assess the effects of both acute and chronic GVHD on survival rate in patients with AML who received HSCT. 
Subjects and Methods: In a longitudinal study, 587 patients with AML who underwent bone marrow 
transplantation in Tehran-Iran between1991 and 2011 were recruited. All patient records were analyzed for 
the occurrence of adverse events including acute and chronic GVHD and leukemia relapse. Data were analyzed 
using Log-rank, Kaplan-Meier, Univariate and Multivariate Cox Regression models.  
Results: The five-year overall survival (OS) was found to be 71.9% (95% CI: 67.40-76.41). Also there was a 
significant relationship between cGVHD and OS (P=0.001, HR = 0.476, 95%). Hazard of death in these 
patients was less than those who did not experience an occurrence of cGVHD and aGVHD (HR= 0.629,            
P= 0.078). A significant relationship between cGVHD and relapse was observed (P< 0.001) indicating that 
patients who developed cGVHD experienced a better survival rate. A significant relationship was also found 
between overall survival and aGVHD grade (P< 0.001). Hazard of death (HD) for cGVHD and relapse variables 
were estimated to be 0.554 and 3.869. 
Discussion: This study is one of the largest studies (regarding the number of participants) done to date in 
the Middle East with quite a long duration (20 years). cGVHD appears to have a positive influence on survival 
rate in patients with AML who received HSCT. It is recommended that further studies investigate the 
underlying reason or mechanisms behind this. 
 




    Allogeneic Hematopoietic Stem Cell 
Transplantation (HSCT) is a curative treatment 
option for many patients with acute myeloid 
leukemia (AML). The effectiveness of HSCT  
 
treatment arises through a combination of the 
cytotoxic effects of the pre-transplantation 
conditioning regimen and the immunological effect 
of transplanted donor cells reacting against the host 
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malignant cells, termed the ‘graft-versus-leukemia’ 
(GVL) effect.  
Despite the success of HSCT, transplantation-
related complications such as graft-versus-host-
disease (GVHD) frequently occur, and can adversely 
affect the quality of life and overall survival.1-3 
GVHD occurs when the donor immune cells from 
the HSCT recognize the normal host tissue as 
foreign, and mount an immunological attack against 
the host. GVHD historically can be classified into 
two forms: acute (aGVHD) and chronic (cGVHD), 
based on whether the disease arises before or after 
the 100th day post transplantation.4  
The occurrence of GVHD, and lack of predictive 
tests to determine which patients are at greater risk 
of developing severe GVHD are still factors 
preventing more widespread use of HSCT, 
particularly in older and frail AML patients. 
However, the situation is further complicated with 
some studies reporting that AML patients 
experiencing GVHD following HSCT actually have a 
lower risk of relapse compared to patients who did 
not experience GVHD, while other studies have 
failed to find any such beneficial relationship 
between GVHD and relapse.5-9 
In this study, the incidence and effects on survival 
rates of both acute and chronic GVHD on 587 AML 
patients (aged <60 years) who underwent HSCT in 
Iran during a twenty-year period between 1991 and 
2011 were evaluated. To the best of the 
researchers’ knowledge this cohort represents the 
largest transplantation dataset in the Middle East, 
and thus provides a good opportunity to investigate 
the occurrence and severity of GVHD and impact on 
outcomes in a large number of patients.  
 
SUBJECTS AND METHODS 
Patients 
   Samples used in this study were obtained from a 
larger longitudinal study on 1012 patients with 
acute lymphoblastic leukemia (ALL) and acute 
myeloid leukemia (AML) that it is believed to 
represent the largest HSCT cohort of leukemia 
patients in the Middle East. In the study presented 
here, data were collected from 587 patients with 
AML (aged <60 years) who underwent bone marrow 
transplantation in the Hematology–Oncology and 
Stem Cell Transplantation Research Center, Shariati 
Hospital, Tehran, Iran between  1991 and 2011. All 
of the written informed consents (No: 124/911019) 
for the hematopoietic cell collection and 
transplantation were obtained from patients and 
donors. Their median follow-up time after 
transplantation was 517 days. All patients’ records 
were reviewed and any occurrence of adverse 
events including GVHD, AML relapse or regimen-
related toxicities was recorded. 
 
Preparative regimen 
The preparative regimen for all patients was 
Busulfan (4 mg/kg/day administered orally on days-
6 to-3) and Cyclophosphamide (60 mg/kg/day by 
intravenous infusion on days-2 to -1) with 
subsequent infusion of donor marrow cells on day 
zero.  
Stem cell transplantation source (SCTs) 
Stem cell transplantation sources among our study 
samples included: peripheral blood (n= 552), bone 
marrow (n= 33) and cord blood (n= 2). Additional 
information is summarized in Table 1. 
 
Prophylaxis and treatment of GVHD 
For GVHD prophylaxis all patients received the 
conventional protocol of Cyclosporin (3 mg/kg/day 
intravenously from days-2) and Methotrexate (10 
mg/m2 day + 1 and 6 mg/m2 on days 3, 6 and 11). 
When oral intake was possible, an oral formulation 
of Cyclosporin was substituted. 
 
GVHD incidence and grading 
The incidence of aGVHD was investigated and 
occurrences were graded I, II, III or IV according to 
the Seattle criteria.10,11 The incidence of cGVHD was 
investigated in all patients who survived for at least 
90 days after transplantation.11-13 
 
Statistical analysis 
The time interval between HSCT and death from 
any cause related to AML or censoring was defined 
as Overall Survival (OS). Censoring was defined as 
being alive at the last follow-up. The Cox 
proportional hazards model was used for 
determination of the relationship between each 
variable and survival time. Furthermore, the 
suitability of the Cox proportional hazards model 
and the best functional form of the independent 
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variables were determined using Cox- Snell residual 
and Martingale residuals, respectively.14 The 
proportional hazard model was used for the 
multivariate analysis of survival.14 However, 
because the Cox proportional assumptions for 
hazard were not met in defining the relationship 
between aGVHD grade and survival, we combined 
grades I and II into a single group for analysis. The 
incidence of cGVHD was investigated in all patients 
who survived for at least 90 days. The probability of 
OS was estimated using Kaplan-Meier estimator.15 
Confidence intervals were calculated via Log 




   Patient characteristics are given in Table 1. Of the 
587 patients included in this study, 233 (39.7 %) 
patients were female with a mean age of 27.27 ± 
12.45 years at transplant time, and 354 (60.3%) 
were male with a mean age of 28.34 ± 12.06 years 
at transplant time. The median survival time of 
patients was 517 days (Range: 7 - 5672 days). The 
first and third quartiles were 153 and 1314 days, 
respectively. The Cumulative incidence of cGVHD 
was 7, 16.8, 30.1 and 36.2 percent at 4, 6, 12, and 
60 months after transplantation. overall survival 
(OS) rate based on Kaplan-Meier curve at 6 months, 
12 months and 5 years was 87.4% (95%, CI: 84.66 -
90.15), 82.2% (95%, CI: 78.87 - 85.54) and 71.9% 
(95%, CI: 67.40 - 76.41), respectively. The five-year 
survival rate was not significantly different between 
patients who developed aGVHD (69.7%; 95% CI: 
63.82 - 75.58) and those that did not develop 
aGVHD (69.7%; 95% CI: 56.96 - 82.44). However, the 
five-year survival rate of patients who developed 
cGVHD was significantly higher (77.3%; 95% CI: 
68.48 - 86.12) than patients who did not develop 
cGVHD (68.2%; 95% CI: 62.52 - 73.89). Furthermore, 
patients who experienced relapse had a significantly 
lower survival rate at 1 year (53.9%; 95% CI: 42.47 -
65.47) and 5 years (30.8%; 95% CI: 18.26 - 43.35) 
after transplantation, compared to patients who 
had not experienced a relapse 1 year (87.2%; 95% 
CI: 84.06 - 90.34) and 5 years (78.9%; 95% CI: 74.40 
- 83.41) after transplantation. According to disease 
stage, the five-year survival rate was76.9% (95% CI: 
72 - 81.8) for the first complete remission (CR1), 
65.5% (95%. CI: 51.98-79.10) for CR2 and 32.8% 
(95%, CI: 7.91-57.68) for CR3. The five-year overall 
survival was calculated for patients who developed 
aGVHD based on grade (І, ІІ, ІІІ and IV); 71.4% (95%, 
CI: 61.6 - 81.2) for grade І, 78.7% (95%, CI: 70.47-
86.94) for grade ІІ, 57.1% (95%, CI: 43.19 - 71.02) for 
grade ІІІ and 40% (95%, CI: 37.28-42.73) for grade 
IV. Overall survival after relapse was 53.9% (95%, CI: 
42.34 - 65.47) at 1 year and 30.8% (95%, CI: 18.26 -
43.35) at 5 years. Cumulative hazard of relapse at 6 
months, 1 and 5 years was 10.4 ± 0.014, 14.8 ± 
0.016and 20.1 ± 0.021, respectively. 
No significant relationship was observed between 
age at transplant time and survival (P= 0.74). Mean 
age of patients at transplant time for who survived 
or died was 27.83 ± 12.02 and 28.23 ± 12.3, 
respectively, but there was a significant relationship 
between hazard of death and donor sex (P=0.014), 
(male patients had a lower survival rate). 
Furthermore, a significant relationship was 
observed between complete remission (CR) status 
and survival rate. Compared to the other groups, 
patients categorized in CR1 had a higher survival 
rate (P< 0.001).  
Results showed that aGVHD developed in 318 
(54.2%) patients. The incidence of cGVHD among 
patients who survived 90 days or longer after 
transplantation was 29.1% (n= 171). We found no 
significant relationship between survival time and 
aGVHD (P= 0.33) (Figure1). However, we found a 
significant relationship between cGVHD and overall 
survival (P=0.001, HR= 0.476, 95%), indicating that 
cGVHD had a protective effect on patient survival 
rate (Figure 2). Among patients who developed 
aGVHD, 38.7% showed cGVHD. Hazard of death in 
patients with both aGVHD and cGVHD was less than 
those who did not develop cGVHD and aGVHD (HR= 
.629, P= 0.078) (Table 2). Overall survival after 
relapse was 53.9% (95%, CI: 42.34 - 65.47) at 1 year 
and 30.8% (95%, CI: 18.26 - 43.35) at 5 years. 
Cumulative hazard of relapse at 6 months, 1 and 5 
years was 10.4 ± 0.014, 14.8 ± 0.016 and 20.1 ± 
0.021, respectively. 
No significant relationship between aGVHD grade 
and survival was detected, using log-rank test (P= 
0.56). Therefore, we combined grade I and II and  
re-analyzed data, using the Cox proportional hazard 
test (Table 2).  
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A significant relationship between overall survival 
and grade of aGVHD was detected in patients                  
(P<0.001), with  patients experiencing grade IV 
aGVHD having a survival rate much worse than any 
other grade of aGVHD (five-year survival rate was 
only 42.9% in grade IV). Hazard of death in patients 
experiencing aGVHD grade ІІІ and IV was 1.8 and 4.2 
times, respectively, more than patients in the 
reference group (Table 2). Hazard of death for 
patients who developed both aGVHD and cGVHD 
was 0.629 compared with the reference group  



































cGVHD) (P= 0.78) (Table 2, Figure 3). Hazard of 
death for patients who developed both aGVHD and 
cGVHD was 0.629 compared with the reference 
group (patients who did not develop either aGVHD 
or cGVHD) (P= 0.78) (Table 2, Figure 3).  
Another categorization for this purpose is shown in 
Figure 4.No significant relationship was observed 
between aGVHD and relapse (P= 0.285), but a 
significant relationship was seen between cGVHD 
and relapse (P<0.001). Patients who developed 
cGVHD showed less relapse or a better survival rate 
(Figure 5). 
 










237 (74.5) 81 (25.5) 318 (100.0)  







225 (83.3) 45 (16.7) 270 (100.0)  
0.56 
Ι 
82 (75.9) 26 (24.1) 108 (100.0) 
II 
101 (82.1) 22 (17.9) 123 (100.0) 
III 
47 (65.3) 25 (34.7) 72 (100.0) 
IV 




143 (83.6) 28 (16.4) 171 (100.0) P<0.001 
No 
318 (76.4) 98 (23.6) 416 (100.0) 
Source 
of  SCTs 
BM 
19 (57.6) 14 (42.4) 33 (100.0) 0.004 
Cord 
1 (50.0) 1 (50.0) 2 (100.0) 
PB 




44 (48.9) 46 (51.1) 90 (100.0) P<0.001 
No 
417 (83.9) 80 (16.1) 497 (100.0) 
CR CR1 
356 (82.03) 78 (17.97) 434 (100.0) P<0.001 
CR2 
75 (78.13) 21 (21.87) 96 (100) 
CR3 
10 (43.48) 13 (56.52) 23 (100.0) 
Donors 
Type 
HLA Mismatch, sibling/other relative 
6 (31.6) 13 (68.4) 19 (100.0) P<0.001 
Other relative, HLA matched 
9 (75.0) 3 (25.0) 12 (100.0) 
Sibling, HLA matched 
446 (80.4) 109 (19.6) 555 (100.0) 
Unrelated 
0 (0.0) 1 (100.0) 1 (100.0) 
GVHD Did not develop aGVHD or cGVHD 
181 (81.9) 40 (18.1) 221 (100.0) P<0.001 
Developed aGVHD or cGVHD 
180 (74.1) 63 (25.9) 243 (100.0) 
Developed both aGVHD and cGVHD 
100 (81.3) 23 (18.7) 123 (100.0) 
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Table 2: Relationship between some variables with survival by using univariateand and multivariate Cox regression in patients 
























*Reference Group. aGVHD: acute Graft versus Host Disease, cGVHD: chronic Graft Versus Host Disease 
 
 
Furthermore, no significant relationship was 
observed between aGVHD and survival rate 
(P=0.33). Meanwhile, there was no significant 
relationship between aGVHD grade and relapse 
(P=0.59).The effects of relapse and cGVHD on 
survival time were analyzed using the multivariate 
Cox regression model. This model showed that 
cGVHD and relapse were two independent factors 
for prediction of survival or death after bone 
marrow transplantation. H (t) = h0 (t) e1.35relape-
0.59cGVHD. Hazard of death for cGVHD was estimated 
to be 0.554. This rate indicates the power of the 
cGVHD variable in increasing survival time. The 
estimated hazard of death was 3.869 for relapse, 
indicating the adverse effect of this variable on 
survival time (Table 2). There was a significant 
relationship between relapse and cGVHD. The risk 
of relapse for patients who developed cGVHD was 
2.92 times lower than those who did not develop 
cGVHD (P<0.001, 95%, CI: 1.69-5). Additional  
 
 
information on relationship between relapse and 
GVHD is summarized in Table 3. 
 
DISCUSSION: 
   HSCT has significant therapeutic benefits to 
patients suffering from hematologic disorders such 
as AML, but the benefits of the stem cell graft can 
be limited by the significant morbidity and mortality 
that can be associated with developing GVHD.17 Our 
objectives were to investigate the incidence of 
GVHD (acute and chronic) and any effects that 
GVHD might have on survival rate on a large cohort 
of patients with AML who underwent HSCT in Iran 
between 1991 and 2011. Previously we found that 
the incidence of cGVHD (among a smaller cohort of 
patients who survived for 90 days or longer after 
transplantation with matched sibling donors) was 
25.5%.18,19 In the current study (a cohort of 587 
patients with more heterogeneous donor type), we 
estimated the incidence of cGVHD to be slightly 
 
                                                      Variable 
 
         HR %       95 CI for HR 
 
    P 









aGVHD  Yes/No        1.198   0.333 1.727 0.333 
 
  
  aGVHD grade 
 
grad І and ІІ         Ref. 
   
 
grad ІІІ 0.007  1.182 0.007 0.007 
 
grad IV P<0.000  2.050 P<0.001 P<0.001 
 
 
cGVHD  Yes/No 0.476  0.001 0.727 0.001 
 
Relapse  Yes/No 4.191 P<0.000 6.054 P<0.001 
    
   GVHD 
 
Did not develop  
aGVHD or cGVHD 
Ref.   
 
Developed  










 aGVHD and cGVHD 0.078 0.375 1.054 0.078 
Multivariate Cox 
Regression Relapse 3.869 P<0.000   5.608 P<0.001 
cGVHD 0.554   0 .007   0.848 0.007 
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Table 3: Relationship between aGVHD and cGVHD and survival according to relapse status in patients with AML who received transplantation in 





















aGVHD: acute Graft versus Host Disease, cGVHD: chronic Graft Versus Host Disease
 
 
higher (29.1%). However, we did not observe any 
significant relationship between survival time and 
aGVHD (P= 0.33) in the present study, which is 
consistent with the results of the previous smaller 
study in which we found that the occurrence of 
aGVHD resulted in a negative (but not significant) 
effect on overall survival (P= 0.11, HR = 0.59).18 
Although cGVHD is usually considered to harbor the 
beneficial graft-versus-leukemia effect, it still 
appears to remain as a single major determinant of 
long-term outcome and quality of life following 
allogeneic transplantation.20 Based on our study 
results, a significant relationship exists between 
survival and cGVHD; however, the literature is 
somewhat conflicting. In a study that was 
conducted by Kataoka et al. no improvement in 
survival rate was observed in patients who 
developed cGVHD,21 however, in our previous 
studies we observed a significant relationship 
between cGVHD and overall survival (P<0.001 exp 
(b) = 3.66)18. In that study, the results indicated that 
OS was about 3.11 times longer in the AML patients 
who developed cGVHD compared to the patients 
who did not develop cGVHD18.cGVHD is largely 
predicted by the prior occurrence of aGVHD.22 
 
Figure 1: Kaplan-Meier estimated survival after transplantation for 
patients with AML in Iran between 1991-2011. There was no 
significant relationship found between the occurrence of aGVHD and 
survival (p=0. 33). aGVHD: acute Graft Versus Host Disease, Yes: 
Survival rate in patients who developed aGVHD, No: Survival rate in 
patients who did not develop aGVHD, No-censored: Time of 
incidence of death in patients who did not develop aGVHD,            








aGVHD Yes 21 (42.0) 29 (58.0) 50 (100.0)  
0.43 No 23 (57.5) 17 (42.5) 40 (100.0) 
cGVHD Yes 8 (50.0) 8 (50.0) 16 (100.0) 0.29 
















0.34 No 201 (87.8) 28 (12.2) 229 (100.0) 
cGVHD Yes 135 (87.1) 20 (12.9) 155 (100.0) 0.01 
No 282 (82.5) 60 (17.5) 342 (100.0) 
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developed cGVHD,21 however, in our previous 
studies we observed a significant relationship 
between cGVHD and overall survival (P<0.001 exp 
(b) = 3.66).18 In that study, the results indicated that 
OS was approximately 3.11 times longer in the AML 
patients who developed cGVHD compared to the 
patients who did not develop cGVHD.18 cGVHD is 
largely predicted by the prior occurrence of 
aGVHD.22 Chronic GVHD is an important clinical 
problem after bone marrow transplantation, and it 
is important to understand if there is any 
relationship between aGVHD and cGVHD in terms 
of both prevention and management. We, 
therefore, analyzed the relationship between 
cGVHD and aGVHD in our cohort. Among patients 
who developed aGVHD, 38.7% showed cGVHD 
Hazard of death in these patients was less than 
those who did not experience cGVHD and aGVHD 
(HR=0.629, P=0.078). However, the relationship 
between these two variables is complex - some data 
suggest that cGVHD is an extension of aGVHD, while 
others suggest it is a distinct entity.23  
Acute and chronic GVHD have been presented as 
favorable in decreasing the risk of AML relapse in 
some studies,24 although in others, results indicated  
that the relapse rate decreased when only aGVHD 
was present.25 In our current study we did not find 
any significant relationship between aGVHD and 
relapse (P=0.285). Although cGVHD causes adverse 
effects, it has also been associated with decreased 
risk of leukemia relapse in a study by Lee et al.26 Our 
study supports these findings with a significant 
relationship observed between cGVHD and relapse 
(P<0.001). In the current study, patients who 
developed cGVHD had better survival rates. In 
patients who developed cGVHD, the risk of relapse 
was 2.92 times lower than patients who did not 
develop cGVHD (P<0.001, 95%, CI: 1.69-5). Several 
observational studies have also demonstrated that 
cGVHD is associated with lower relapse rates.26-30 In 
yet another study, cGVHD was associated with a 
lower relapse risk in all diagnoses.31 Kim et al. 
(2007) did not find any association between relapse 
rate with cGVHD.25 
In a smaller AML cohort using a multivariate model, 
overall survival had a strong relationship with 
relapse (exp (b) = 10.58, P<0.001).18 Our current 
study indicates that a hazard of death score in 
patients who relapsed was 3.869 times worse than 
patients who had not relapsed, supporting the 
relationship found in the smaller study. The overall 
survival (OS) rate based on Kaplan-Meier curve in 
our AML patient cohort with the median survival 
time of 517 (17.2 months) days in 6 months, 1 and 5 
years was 87.4% (95%, CI: 84.66 - 90.15), 82.2% 
(95%, CI: 78.87 - 85.54) and 71.9% (95%, CI: 67.40 -
76.41), respectively. The 5-year survival reported in 
our study is much longer than that reported in 
other studies e.g. the 3-year survival calculated by 
Baron et al. was 54 ± 1%,32 and the 5-year overall 
survival reported by Mitus et al. for their entire 
cohort of patients was 55%33 from date of 
diagnosis. The 5-year survival rate reported in our 
study is similar to those previously reported by us 
based on smaller sample size, it was 65% (95% CI: 
60.7 - 69.3).18,19 Additionally, we found that the 
patients in our current cohort had higher median 
survival time compared to other studies (17.2 Vs. 9 
months).34 
Based on our study, a significant relationship 
between overall survival and aGVHD grade was 
detected (P<0.001), so those patients who 
experienced grade IV aGVHD had a much lower 
survival rate than patients who experienced milder 
grades of aGVHD. In another study, significant 
improvement was detected in overall survival 
among AML patients who developed grade I acute 
GVHD (P = 0.0002).6 Relapse rate was lower in grade 
I acute GVHD than in grade II.6 Moreover, in a 
similar study performed by Baron et al, it was 
shown that grade I aGVHD was associated with a 
lower risk of relapse (hazards ratio (HR) = 0.7, P= 
0.02. grade II aGVHD had no net impact on OS, 
while grade III-IV aGVHD was associated with a 
worse OS (HR= 0.4, P<0.0.001) owing to high risk of 
non-relapse mortality (NRM; HR= 5.2, P<0.0001).32 
However, in our study, we were unable to find any 
significant relationship between these variables 
(P=0.39). Five-year overall survival in patients with 
aGVHD (I, II, III and IV) was 71.4% (95%, CI: 61.6 -
81.2), 78.7% (95%, CI: 70.47 - 86.94), 57.1% (95%, 
CI: 43.19 - 71.02) and 40% (95%, CI: 37.28 - 42.73), 
respectively, while in the similar study, 4-year OS 
was 66 ± 2% in patients with grade I acute GVHD, 
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Figure 2:  Kaplan-Meier estimated survival after transplantation for 
patients with AML in Iran between 1991 and 2011. Patients who 
developed cGVHD had a higher survival rate than patients who did 
not develop cGVHD (p<0.001). cGVHD: chronic Graft Versus Host 
Disease, Yes: Survival rate in patients who developed cGVHD, No: 
Survival rate in patients who did not develope cGVHD, No-
censored: Time of incidence of death in patients who did not 
develope cGVHD, Yes-censored: Time of incidence of death in 
patients who developed  cGVHD 
 
Figure 3: Kaplan-Meier estimated survival based on GVHD status 
for AML patients who received transplantation in Iran between 
1991 and 2011. There was a significant relationship between 
survival and grade-aGVHD (p<0.001). GVHD: Graft Versus Host 
Disease, 0: did not develop aGVHD or cGVHD, 1:  Developed aGVHD 
or cGVHD and 2:  developed both aGVHD and cGVHD 
 
Figure 4: Kaplan-Meier estimated relationship between GVHD and 
Hazard of Death in AML patients who received transplantation in 
Iran between 1991 and 2011. There was a significant relationship 
between survival and GVHD (p=0.002). Group 1: The patients who 
developed cGVHD only, Group 2: The patients who developed both 
aGVHD and cGVHD, Group 3: The patients who did not develop 
either aGVHD or cGVHD and Group 4: The patients who only 
developed aGVHD, 1-censored: Time of incidence of death in group 
1, 2-censored: Time of incidence of death in group 2, 3-censored: 
Time of incidence of death in group 3, 4-censored: Time of 
incidence of death in group 4 
 
Figure 5: Kaplan-Meier estimated relationship between cGVHD and 
relapse time for AML patients who received transplantation in Iran 
between 1991 and 2011. There was a significant relationship 
between survival and relapse time (p<0.001). Chronic Graft Versus 
Host Disease, No: Survival rate for patients who did not develope 
cGVHD, Yes: Survival rate for patients who developed cGVHD, No-
censored: Time of incidence of death in patients who did not 
develope cGVHD, Yes-censored: Time of incidence of death in 
patients who developed cGVHD 
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60 ± 2% in patients without acute GVHD, 56 ± 4% in 
patients with grade II acute GVHD and 43 ± 4% in 
patients with grade III–IV acute GVHD.32  
No significant relationship was seen between age at 
transplant time and survival (P= 0.74), which is 
consistent with previous studies.19 Based on the 
results of our study, there was a significant 
relationship between donor sex and hazard of death 
(P=0.014). This is also consistent with our previous 
findings.19 
Overall Survival (OS) after relapse was 53.9% (95%, 
CI: 42.34 - 65.47) and 30.8% (95%, CI: 18.26 - 43.35) 
at 1 and 5 years, respectively, much higher than 
what was reported in another study in which the OS 
after relapse was as low as 19.3% at 3 years.35  
Our results suggest that cGVHD has a positive 
influence on the survival rate of patients with AML. 
However, based on our findings, prior occurrence of 
aGVHD in patients who later developed cGVHD 
could result in an increase in the hazard of death 
score. We recommend that further work needs to 
be done to investigate this link and whether it might 
influence patient survival.  
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